{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:53:43Z","timestamp":1781506423331,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1304500"],"award-info":[{"award-number":["2022YFA1304500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Center of Technology Innovation for Biopharmaceuticals","award":["NCTIB2023XB01014"],"award-info":[{"award-number":["NCTIB2023XB01014"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["HY2021\u20137"],"award-info":[{"award-number":["HY2021\u20137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies but remains limited by on-target, off-tumor toxicity and the lack of precise mechanisms to restrain aberrant activation. Inhibitory CARs (iCARs) offer a logic-gated strategy to suppress unwanted immune responses, yet optimization of inhibitory signaling modules has been hindered by an incomplete understanding of immunoreceptor tyrosine-based inhibitory motif (ITIM) diversity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established a systematic screening platform to evaluate ITIM-containing intracellular domains (ICDs) from 35 candidate receptors. Using nuclear factor of activated T cells (NFAT) reporter assays across multiple activation contexts, we quantified the ability of each domain to counteract iimmunoreceptor tyrosine-based activating motif (ITAM)-mediated signaling. Intracellular truncated analyses tested the requirement of intact cytoplasmic motifs, and the most potent ITIMs were incorporated into iCAR architectures to assess their capacity to inhibit CAR-driven effector responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 12 ITIM domains that strongly suppressed NFAT signaling across diverse activation states. Their inhibitory activity required intact ITIM motifs. When integrated into iCAR constructs, these domains conferred markedly greater suppression of CAR-induced activation compared with conventional programmed cell death protein 1 (PD-1)-based designs. Among them, the SIGLEC9-derived ITIM exhibited the most potent inhibition, significantly reducing CAR-T effector function and protecting target cells from cytotoxicity in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified distinct intracellular modules that effectively suppress CAR-mediated activation, with the SIGLEC9-derived ITIM exhibiting the strongest inhibition. Leveraging domain-specific inhibitory strength enables precise and modular control of T-cell activation, thereby improving the safety, specificity, and tunability of next-generation cellular immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbag010","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:35:56Z","timestamp":1773146156000},"page":"150-158","source":"Crossref","is-referenced-by-count":0,"title":["Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T"],"prefix":"10.1093","volume":"9","author":[{"given":"Ting","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University , Beijing 100191 ,","place":["China"]},{"name":"State Key Laboratory of Molecular Oncology, Frontiers Science Center for Cancer Integrative Omics, Peking University International Cancer Institute, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University , Beijing 100191 ,","place":["China"]},{"name":"State Key Laboratory of Molecular Oncology, Frontiers Science Center for Cancer Integrative Omics, Peking University International Cancer Institute, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University , Beijing 100191 ,","place":["China"]},{"name":"State Key Laboratory of Molecular Oncology, Frontiers Science Center for Cancer Integrative Omics, Peking University International Cancer Institute, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University , Beijing 100191 ,","place":["China"]},{"name":"State Key Laboratory of Molecular Oncology, Frontiers Science Center for Cancer Integrative Omics, Peking University International Cancer Institute, Peking University , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4291-0144","authenticated-orcid":false,"given":"Mi","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University , Beijing 100191 ,","place":["China"]},{"name":"State Key Laboratory of Molecular Oncology, Frontiers Science Center for Cancer Integrative Omics, Peking University International Cancer Institute, Peking University , Beijing 100191 ,","place":["China"]},{"name":"Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute , Beijing 100142 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026061502262664200_ref1","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"2026061502262664200_ref2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2026061502262664200_ref3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026061502262664200_ref4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061502262664200_ref5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"2026061502262664200_ref6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"2026061502262664200_ref7","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.3390\/curroncol30050378","article-title":"Management and prevention of cellular-therapy-related toxicity: early and late complications","volume":"30","author":"Mucha","year":"2023","journal-title":"Curr Oncol"},{"key":"2026061502262664200_ref8","doi-asserted-by":"publisher","first-page":"e008566","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026061502262664200_ref9","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","article-title":"CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations","volume":"8","author":"Perna","year":"2024","journal-title":"Blood Adv"},{"key":"2026061502262664200_ref10","doi-asserted-by":"publisher","first-page":"799206","DOI":"10.3389\/fimmu.2021.799206","article-title":"Single-cell analysis of target antigens of CAR-T reveals a potential landscape of \"on-target, off-tumor toxicity\"","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2026061502262664200_ref11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","article-title":"Novel strategies to manage CAR-T cell toxicity","volume":"24","author":"Mulvey","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026061502262664200_ref12","doi-asserted-by":"publisher","first-page":"eadj6251","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"key":"2026061502262664200_ref13","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026061502262664200_ref14","doi-asserted-by":"publisher","first-page":"e2312374120","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026061502262664200_ref15","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.critrevonc.2025.104824","article-title":"Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies","volume":"214","author":"Wang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026061502262664200_ref16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2016.01.007","article-title":"Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: simultaneous measurement of NF-\u03baB, NFAT and AP-1","volume":"430","author":"Jutz","year":"2016","journal-title":"J Immunol Methods"},{"key":"2026061502262664200_ref17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molimm.2020.09.012","article-title":"Engineered T cells directed at tumors with defined allelic loss","volume":"128","author":"Hamburger","year":"2020","journal-title":"Mol Immunol"},{"key":"2026061502262664200_ref18","doi-asserted-by":"publisher","first-page":"e003826","DOI":"10.1136\/jitc-2021-003826","article-title":"Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells","volume":"10","author":"Tokatlian","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026061502262664200_ref19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026061502262664200_ref20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat Commun"},{"key":"2026061502262664200_ref21","doi-asserted-by":"publisher","first-page":"102225","DOI":"10.1016\/j.tranon.2024.102225","article-title":"Modified CD15\/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia","volume":"52","author":"Zhang","year":"2025","journal-title":"Transl Oncol"},{"key":"2026061502262664200_ref22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13024-022-00550-y","article-title":"LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions","volume":"17","author":"Zhao","year":"2022","journal-title":"Mol Neurodegener"},{"key":"2026061502262664200_ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14:5983","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"2026061502262664200_ref24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026061502262664200_ref25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med"},{"key":"2026061502262664200_ref26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.290.5489.84","article-title":"Immune inhibitory receptors","volume":"290","author":"Ravetch","year":"2000","journal-title":"Science"},{"key":"2026061502262664200_ref27","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"2026061502262664200_ref28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/01.HYP.11.6.602","article-title":"Role of the nucleus ambiguus in the regulation of heart rate and arterial pressure","volume":"11","author":"Machado","year":"1988","journal-title":"Hypertension"},{"key":"2026061502262664200_ref29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"2026061502262664200_ref30","doi-asserted-by":"publisher","first-page":"eaay4458","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci Adv"},{"key":"2026061502262664200_ref31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"2026061502262664200_ref32","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1021\/bi301461t","article-title":"Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1","volume":"52","author":"Tourdot","year":"2013","journal-title":"Biochemistry"},{"key":"2026061502262664200_ref33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","article-title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation","volume":"3","author":"Patsoukis","year":"2020","journal-title":"Commun Biol"},{"key":"2026061502262664200_ref34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ymthe.2024.02.022","article-title":"Inhibitory CARs fail to protect from immediate T cell cytotoxicity","volume":"32","author":"Funk","year":"2024","journal-title":"Mol Ther"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag010\/67298643\/tbag010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/2\/150\/67298643\/tbag010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/2\/150\/67298643\/tbag010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:26:36Z","timestamp":1781504796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/2\/150\/8514076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag010","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,11]]}}}